Evidence & Access

We strengthen the scientific decisions that build healthcare provider’s confidence in treatment innovation.

Combining deep expertise in Health Economics, Outcomes Research, Real-World Evidence, Patient-Centred Outcomes, and Market Access, we generate the evidence, insights, and strategic guidance needed to demonstrate value, navigate complexity, and secure reimbursement and access. Our multidisciplinary teams transform scientific evidence into actionable decisions that improve patient outcomes and maximise commercial success.

How we help

Effective treatments only reach patients when stakeholders have the confidence to make informed decisions.

We help clients navigate complexity by turning evidence into decision-ready insight, demonstrating value, and supporting access and reimbursement decisions.

Combining scientific rigour with strategic expertise, we bring clarity and confidence to the decisions that shape patient access, commercial success, and healthcare outcomes.

Our services

Strengthening the access decisions that determine whether innovation reaches patients.

to transform insights into initiatives that impact outcomes, quality of life and elevate hope through communication and collaboration.

  • Real-World Evidence (RWE)

    Generates real-world evidence on disease burden, treatment patterns, effectiveness and costs. Uses diverse data sources to inform value, access and decision-making beyond trials

  • Modelling & Meta-Analysis

    Builds economic models and comparative analyses to demonstrate clinical and economic value. Synthesises evidence to support HTA submissions, pricing and reimbursement decisions

  • Patient Support Content

    Captures outcomes, quality of life and preferences that matter to patients Integrates the patient voice into evidence generation and value stories

  • Strategic Market Access (SMA)

    Defines global and local payer, HTA and access strategies Translates evidence into clear value communication for reimbursement and access

By the numbers

Evidence & Access at-a-glance

Our scale is not just about reach. It’s how we bring the right expertise, at the right moment, to support better decisions. Across geographies, disciplines, and the product lifecycle, we combine depth and connectivity to deliver impact where it matters most.

  • 1,000+

    HEOR & Market Access specialists

  • 14+

    Years of experience

  • 6

    Continents / global reach

Proven & trusted

In our clients' words

  • …despite the newness of the core PE model, I appreciate how your team was able to deliver such a solid final Canadian PE model for CADTH, as well as your agile support in responding to CADTH’s model/NMA comments.

    Associate Manager; Pricing, Reimbursement, and Access – Top 5 Pharma company

  • Congratulations to all of you as our partners in this amazing journey to provide access of [X] to patients in need of this medicine. I know how hard you all have worked in supporting us with [X] – right from the beginning when [we were discussing the de novo modeling – Thank you so much!

    Client – Top 35 Pharma company

  • A big thank you from all of u s to every one of you for your commitment, dedication, the great collaboration, and the excellent support for our affiliates – without that, their business wouldn’t be possible.” Senior Research Scientist Global – Top 5 Pharma company

    Senior Research Scientist Global – Top 5 Pharma company

Meet the experts

Experts who strengthen the access decisions

  • Elisabeth Fenwick PhD

    Chief Scientific Officer

    Every engagement begins with the decision our client needs to make. We shape the strategy first, then calibrate the evidence, expertise and technology to the question, audience and decision it must support.

  • Ben van Hout

    Scientific Founder at OPEN Health HEOR & Market Access

    The real measure of our work isn’t simply the strength of the evidence we generate. It’s whether that evidence can withstand scrutiny, demonstrate meaningful value and ultimately help the right innovation reach the patients who need it.

Talk to our Evidence and Access team